<DOC>
	<DOCNO>NCT01222949</DOCNO>
	<brief_summary>The Study design evaluate pharmacokinetics DHA PQ healthy volunteer assess effect ethnicity ( Asian v Caucasian ) , gender body weight relative bioavailability DHA PQ .</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Trial Healthy Asian Caucasian Volunteers Investigating PK Profile Eurartesimâ„¢</brief_title>
	<detailed_description />
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Caucasian Asian healthy subject , Male female , age 18 50 year ( inclusive ) Body Mass Index ( BMI ) 19.0 kg/m2 27.0 kg/m2 inclusive , minimum body weight 36 kg . Agreed use two approve method contraception Had give write informed consent participate study accordance local regulation Had receive anticipated receive prescription medication within 14 day prior start dose Pregnant lactating ( female ) Abnormal laboratory test result deem clinically significant screen Positive urine drug test alcohol breath test Acute therapy serious infection within 30 day study entry History significant drug allergy significant allergic reaction Had participate clinical trial receive experimental therapy within 30 day 10 halflives drug Receipt blood blood product , loss donation 450 mL blood within 90 day first dose administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>